TipRanks
Go Ultimate55% OFF

Colan Totte.Co.,Ltd. (7792) AI Stock Analysis

JP:7792

Colan Totte.Co.,Ltd.

(TSE/TYO:7792)

Select Model
Rating:90Outperform
Price Target:JPY 1,759.00â–²(23.79% Upside)
Action:reiterated
Date:08/04/26

Colan Totte Co., Ltd. presents an outstanding investment profile driven by exceptional profitability, a nearly debt-free balance sheet, and a highly attractive valuation. The stock trades at a compelling P/E ratio of 9.7 while offering a solid dividend yield, backed by a strong return on equity. Technical indicators point to steady upward momentum across key moving averages, reinforcing the stock's overall strength and minimizing immediate downside risk.

Positive Factors
High profit marginsSustained high gross (67.33%) and net (19.20%) margins indicate durable pricing power and an efficient cost structure in the medical-devices business. These margins create long-term cash flow cushion, support reinvestment in R&D, and give flexibility to sustain profits through industry cycles.
Negative Factors
Free cash flow volatilityHistorical volatility in free cash flow undermines predictability for funding capex, R&D and shareholder returns. Even with strong conversion ratios on average, intermittent FCF declines can force management to curtail investments or dividends, limiting strategic flexibility over the medium term.

Colan Totte.Co.,Ltd. (7792) vs. iShares MSCI Japan ETF (EWJ)

-10%-5%0%5%10%15%20%25%30%JP:7792-0.09%EWJ+16.91%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 13.08B
Dividend Yield
3.52%
Average Volume (3M)
14.32K
Price to Earnings (P/E)
9.1
Beta (1Y)
0.53
Revenue Growth
33.43%
EPS Growth
12.57%
Country
Japan
Employees
104
Sector
General
Sector Strength
55
Industry
Medical - Devices

Colan Totte.Co.,Ltd. Business Overview & Revenue Model

Company Description

Colan Totte Co., Ltd., established in Osaka, Japan, in 1997, operates as an international firm specializing in the development and global distribution of therapeutic devices under its proprietary Colantotte brand. The company's diverse product portfo...

How the Company Makes Money

null

Colan Totte.Co.,Ltd. Financial Statement Overview

Summary

Exceptional financial profile featuring robust margins (19.2% net profit), an unlevered balance sheet (0.002 D/E ratio), and strong free cash flow generation, reflecting excellent operational efficiency.

Income Statement

92Very Positive

Balance Sheet

96Very Positive

Cash Flow

84Very Positive
Financial statement breakdown
BreakdownTTMSep 2025Sep 2024Sep 2023Sep 2022Sep 2021
Income Statement
Total Revenue8.02B6.92B5.94B5.41B4.66B3.71B
Gross Profit5.46B4.66B3.97B3.45B3.04B2.46B
EBITDA2.06B1.90B1.57B1.10B1.02B691.13M
Net Income1.35B1.33B1.02B645.02M610.45M420.50M
Balance Sheet
Total Assets7.18B6.74B5.43B4.91B4.13B3.62B
Cash, Cash Equivalents and Short-Term Investments2.11B2.18B1.76B1.79B1.34B1.55B
Total Debt8.05M12.90M8.69M1.27M270.48M439.84M
Total Liabilities1.62B1.57B1.32B1.64B1.38B1.38B
Stockholders Equity5.55B5.17B4.11B3.27B2.75B2.24B
Cash Flow
Free Cash Flow1.06B728.70M357.26M867.34M75.48M597.37M
Operating Cash Flow1.48B998.35M883.77M955.70M148.09M637.27M
Investing Cash Flow-471.40M-303.40M-736.91M-83.80M-80.38M-51.45M
Financing Cash Flow-654.18M-272.18M-180.15M-410.10M-274.23M452.40M

Colan Totte.Co.,Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price1421.00

Price Trends

50DMA1444.63Negative
100DMA1422.60Negative
200DMA1412.99Positive

Market Momentum

MACD-3.67Positive
RSI38.13Neutral
STOCH12.27Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7792, the sentiment is Negative. The current price of 1421.00 is below the 20-day moving average (MA) of 1461.40, below the 50-day MA of 1444.63, and above the 200-day MA of 1412.99, indicating a neutral trend. The MACD of -3.67 indicates Positive momentum. The RSI at 38.13 is Neutral, neither overbought nor oversold. The STOCH value of 12.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7792.

Colan Totte.Co.,Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:7792 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:7792JP:779290OutperformJPY 13.12B9.14―3.52%33.43%12.57%
JP:5187JP:518770OutperformJPY 10.13B16.63―4.27%3.38%-52.61%
JP:6523JP:652358NeutralJPY 180.17B19.395.76%2.99%3.04%-19.26%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:4549JP:454950NeutralJPY 76.06B39.82―2.59%3.92%-52.01%
JP:7600JP:760047NeutralJPY 15.22B-67.86―2.94%-6.64%67.08%
JP:6849JP:684946NeutralJPY 265.01B18.99―2.01%1.43%1.86%

* General Sector Average

Performance Comparison

0%50%100%JP:7792JP:6523JP:4549JP:5187JP:6849JP:7600Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:7792 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:7792Colan Totte.Co.,Ltd.1421.00-27.39-1.89%
JP:6523PHC Holdings Corp.1405.00412.4341.55%
JP:4549Eiken Chemical Co., Ltd.2238.00-95.34-4.09%
JP:5187Create Medic Co., Ltd.1123.00146.2214.97%
JP:6849Nihon Kohden Corporation1589.50-157.88-9.04%
JP:7600Japan Medical Dynamic Marketing, Inc.568.0088.5018.46%

Colan Totte.Co.,Ltd. Corporate Events

Colan Totte Lifts Sales, Guidance and Dividend on Strong First‑Half Earnings

May 8, 2026

Colan Totte reported robust non‑consolidated results for the six months ended March 31, 2026, with net sales rising 34.1% year on year to ¥4.33 billion and operating profit up 18.2% to ¥1.12 billion, while profit edged up 3.3% to &#16...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 04, 2026